Add to ORKGIn 2011, the Australian and New Zealand governments announced their decision to proceed with a joint scheme for the regulation of therapeutic products such as medicines, medical devices and new medical interventions. Eventually, the joint arrangements will be administered by a single regulatory entity: the Australian and New Zealand Therapeutic Products Agency (ANZTPA). The rationale for establishing ANZTPA is based on public health and economic principles. This paper explores the strengths and weaknesses of the proposed therapeutic products legislation, which will repeal the Medicines Act (NZ) - the Therapeutic Products and Medicines Bill
This paper considers the recent global concern of psychoactive substance use alongside New Zealand’s...
Tobacco is a particularly unusual consumer product in that it is highly addictive, kills over half i...
Introduction: There is disagreement about whether New Zealand is falling behind in access to medicin...
In 2011, the Australian and New Zealand governments announced their decision to proceed with a joint...
Australia and New Zealand had agreed in principle to the creation of a single agency for the regulat...
This article evaluates New Zealand’s Medicines Amendment Bill 2011. This Bill is currently before Pa...
Medical devices encompass everything from simple bandages to complex machinery and software, and are...
Purpose of this discussion paper This paper is being released to promote discussion and to assist th...
The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceu...
1. Australia has, by a number of different measures (life expectancy, survival with cardiovascular d...
This paper deals with Direct-to-consumer advertising (DTCA) for prescription drugs in New Zealand. T...
The Trans-Pacific Partnership is a multilateral free-trade agreement, which New Zealand became a par...
Recent legal developments have highlighted the need for greater support from the Federal Government ...
Research Doctorate - Doctor of Philosophy (PhD)In January 2005 Australia implemented the Australia-U...
This consultation paper explores what legislative reforms, and other changes, would be needed if New...
This paper considers the recent global concern of psychoactive substance use alongside New Zealand’s...
Tobacco is a particularly unusual consumer product in that it is highly addictive, kills over half i...
Introduction: There is disagreement about whether New Zealand is falling behind in access to medicin...
In 2011, the Australian and New Zealand governments announced their decision to proceed with a joint...
Australia and New Zealand had agreed in principle to the creation of a single agency for the regulat...
This article evaluates New Zealand’s Medicines Amendment Bill 2011. This Bill is currently before Pa...
Medical devices encompass everything from simple bandages to complex machinery and software, and are...
Purpose of this discussion paper This paper is being released to promote discussion and to assist th...
The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceu...
1. Australia has, by a number of different measures (life expectancy, survival with cardiovascular d...
This paper deals with Direct-to-consumer advertising (DTCA) for prescription drugs in New Zealand. T...
The Trans-Pacific Partnership is a multilateral free-trade agreement, which New Zealand became a par...
Recent legal developments have highlighted the need for greater support from the Federal Government ...
Research Doctorate - Doctor of Philosophy (PhD)In January 2005 Australia implemented the Australia-U...
This consultation paper explores what legislative reforms, and other changes, would be needed if New...
This paper considers the recent global concern of psychoactive substance use alongside New Zealand’s...
Tobacco is a particularly unusual consumer product in that it is highly addictive, kills over half i...
Introduction: There is disagreement about whether New Zealand is falling behind in access to medicin...